Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.62 |
| ▸ | VNN1 | O95497 | 9/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8105775 | 0.87 | GSK3B (0.74) | GSK3BVNN1GRM5MAPTFFAR1 | |
| SCHEMBL19707531 | 0.84 | GSK3B (0.62) | GSK3BGRM5L3MBTL1 | |
| SCHEMBL10745445 | 0.83 | GSK3B (0.70) | GSK3BVNN1GRM5NAMPT | |
| SCHEMBL19707546 | 0.83 | GSK3B (0.60) | GSK3BL3MBTL1LMNAMAPTTDP1 | |
| SCHEMBL19707549 | 0.82 | GSK3B (0.59) | GSK3BL3MBTL1LMNAMAPTTDP1 | |
| SCHEMBL13571053 | 0.81 | GSK3B (0.66) | GSK3BVNN1GRM5L3MBTL1FFAR1 | |
| SCHEMBL31542041 | 0.81 | GSK3B (0.66) | GSK3BVNN1LMNAFFAR1HDAC3 | |
| SCHEMBL12354562 | 0.80 | GSK3B (0.53) | GSK3BVNN1TDP1MRGPRX4 | |
| SCHEMBL12586951 | 0.79 | TDP1 (0.51) | GSK3BVNN1TDP1MRGPRX4 | |
| SCHEMBL1712250 | 0.78 | GSK3B (0.72) | GSK3BVNN1GRM5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128718-A1 | Tetrahydropyridazine derivatives having a pesticidal effect | BAYER CROPSCIENCE AG (DE) | 2006-06-15 | — | — | US | disclosed |
| US-20050150764-A1 | Tetrahydropyridazine derivatives and their use as pesticides | MAURER FRITZ (DE) | 2005-07-14 | — | — | US | disclosed |
| EP-1537101-A1 | TETRAHYDROPYRIDAZINE DERIVATIVES HAVING A PESTICIDAL EFFECT | Bayer CropScience Aktiengesellschaft (DE) | 2005-06-08 | — | — | EP | disclosed |
| EP-1414815-A1 | TETRAHYDROPYRIDAZINE DERIVATIVES AND THEIR USE AS PESTICIDES | Bayer CropScience AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2004024722-A1 | TETRAHYDROPYRIDAZINE DERIVATIVES HAVING A PESTICIDAL EFFECT | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003010162-A1 | TETRAHYDROPYRIDAZINE DERIVATIVES AND THEIR USE AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050150764-A1 | Tetrahydropyridazine derivatives and their use as pesticides | DDT, ACHE, CYP4X1 | GSK3B 3372/4885VNN1 2346/4885GRM5 25/4885 |
| US-20060128718-A1 | Tetrahydropyridazine derivatives having a pesticidal effect | DDT, ACHE, RDX | GSK3B 3531/4885VNN1 2551/4885GRM5 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.